Scarica l'app Stockscreener
67.48
1.23%
-0.84
Pre-mercato:
67.04
-0.44
-0.65%
Precedente Chiudi:
$68.32
Aprire:
$67.83
Volume 24 ore:
1.82M
Relative Volume:
1.25
Capitalizzazione di mercato:
$12.87B
Reddito:
$2.75B
Utile/perdita netta:
$322.29M
Rapporto P/E:
40.41
EPS:
1.67
Flusso di cassa netto:
$300.88M
1 W Prestazione:
-7.35%
1M Prestazione:
-4.98%
6M Prestazione:
-1.00%
1 anno Prestazione:
-22.24%
Intervallo 1D:
$67.28
$68.54
Intervallo di 1 settimana:
$67.28
$72.81
Portata 52W:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
67.48 | 12.87B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Edmond DE Rothschild Holding S.A. Boosts Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (BMRN) - Seeking Alpha
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study - Yahoo Finance
Nomura Asset Management Co. Ltd. Sells 73,310 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin’s PALYNZIQ shows promise for adolescents with PKU - Investing.com India
BioMarin’s PALYNZIQ shows promise for adolescents with PKU By Investing.com - Investing.com South Africa
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Benzinga
BioMarin succeeds in trial for its metabolic disorder treatment - MSN
BioMarin's Trial for Phenylketonuria Shows Palynziq Reduces Blood Phenylalanine in Adolescents - MarketScreener
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance
Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales - MSN
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
US FDA approves Sanofi's bleeding disorder therapy - MarketScreener
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lifted by Sector Gamma AS - MarketBeat
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharm - GuruFocus
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - Yahoo Finance
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock By Investing.com - Investing.com Australia
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock - Investing.com India
Citi maintains Neutral on BioMarin stock, price target at $82 - Investing.com
BioMarin Pharmaceutical (BMRN): Among Paul Singer’s Latest Portfolio’s Top Stock Picks - Insider Monkey
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) - PR Newswire
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires? - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why - TradingView
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
544 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by SBI Securities Co. Ltd. - Defense World
Smartleaf Asset Management LLC Increases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
4 Discounted PEG Stocks Offering the Best Returns to Value Investors - Yahoo Finance
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at StockNews.com - Defense World
BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire
Proficio Capital Partners LLC Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin at TD Cowen Conference: Strategic Growth and Innovation - Investing.com
First Week of October 17th Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Phenylketonuria Treatment Market Projected To Witness Substantial Growth, 2025-2032: BioMarin Pharmaceutical - EIN News
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):